[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100437779":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":18,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":18,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":18,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":39,"whyStopped":18,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"The early intervention group","EXPERIMENTAL","The early intervention group: evaluation and intervention based on impedance cardiography results at multiple timepoints. Specific intervention measures include:\n\n1. cardiovascular drug treatment: based on the increase and decrease of the \"Golden Triangle\"\n\n   1. ACEI, perindopril tert-butyrate 4mg qd\n   2. β receptor antagonist, metoprolol succinate 47.5mg qd\n   3. Spironolactone 20mg qd\n   4. Drugs to improve myocardial metabolism: trimetazidine hydrochloride 35 mg bid\n   5. Other therapeutic drugs include: loop diuretics, ARNI, sinus node If current selection specific inhibitors, statins, antiplatelet aggregation and nitrate drugs, etc.\n2. Exercise intervention: exercise prescription based on the initial cardiopulmonary exercise test results.",[13],"Drug: Multiple cardiovascular drugs related to \"Golden Triangle\"",{"label":15,"type":16,"description":17,"interventionNames":18},"The control group","NO_INTERVENTION","This group will be under observation. When cardiovascular events (including ischemic cardiomyopathy, heart failure, arrhythmia requiring treatment, pericardial disease requiring treatment, valvular disease, etc.) happen, a cardiovascular specialist assessment and intervention will be given.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Multiple cardiovascular drugs related to \"Golden Triangle\"","Based on impedance cardiography results at each timepoints, cardiovascular drug treatment and exercise plan will be given in the intervention group.",[9],[26],{"name":27,"affiliation":28,"role":29},"Hui Liu, Professor","Sun yat-sen universtiy cancer center","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Bo Qiu","CONTACT","+862087343031","qiubo@sysucc.org.cn",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Sun yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":46,"coordinates":47},"Point",[48,49],113.25,23.11667,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":34,"phoneExt":18,"email":18},"Bo Qiu, Professor",{"type":29,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Hui Liu","Professor","100437779","phase-3-early-specialized-cardiovascular-intervention-based-on-impedance-cardiography-in-locally-advanced-non-small-cell-lung-cancer-patients-100437779",false,"NCT04980716","Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients Who Receiving Radical Concurrent Chemoradiotherapy and Immunotherapy: a Prospective, Randomized Controlled, Multicenter Phase III Clinical Trial.","Inclusion Criteria:\n\n1. It is diagnosed as non-small cell lung cancer by pathological examination or cytological examination; it is assessed as locally advanced, unresectable stage III non-small cell lung cancer by imaging;\n2. Plan to receive radical radiotherapy and chemotherapy ± immunotherapy;\n3. Male or female between 18 and 75 years old;\n4. Life expectancy ≥ 12 weeks;\n5. The World Health Organization (WHO) PS score is 0 or 1;\n6. Organ and bone marrow function meet the following conditions: Forced expiratory volume per second (FEV1) ≥1000 ml; absolute neutrophil count ≥1.5×10\\^9\u002FL; platelets ≥100×10\\^9\u002FL; hemoglobin ≥90 g\u002FL ; Serum creatinine clearance calculated according to the Cockcroft-Gault formula ≥50 mL\u002Fmin (Cockcroft and Gault 1976); serum bilirubin ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase and aspartate aminotransferase ≤2.5 times ULN;\n7. A signed informed consent form is required before proceeding with any step in the research;\n8. There is an abnormality in the initial cardiac output index.\n\nExclusion Criteria:\n\n1. PS score 2-4;\n2. Organ function impairment: FEV1 \\\u003C1000ml; absolute neutrophil count \\\u003C1.5×10\\^9\u002FL; platelets \\\u003C100×10\\^9\u002FL; hemoglobin \\\u003C90 g\u002F L; Serum creatinine clearance calculated according to Cockcroft-Gault formula \\\u003C50 mL\u002Fmin; serum bilirubin\\>1.5 times ULN; alanine aminotransferase and aspartate aminotransferase\\>2.5 times ULN;\n3. Unstable angina or myocardial infarction occurred in the past month;\n4. Arrhythmia that has not been controlled and can cause symptoms or abnormal hemodynamics;\n5. Active endocarditis;\n6. Symptomatic severe aortic stenosis;\n7. Heart failure that has not been controlled;\n8. Acute pulmonary embolism, pulmonary infarction or low thrombosis (artery or vein) formation;\n9. Suspected or confirmed aortic dissection;\n10. Uncontrolled bronchial asthma;\n11. Pulmonary edema;\n12. Fingertip blood oxygen saturation at rest ≤85%;\n13. Acute non-cardiopulmonary diseases (such as infection, renal failure, thyrotoxicosis, etc.) that may affect sports performance or aggravate due to exercise;\n14. Mental disorders make it impossible to cooperate.\n15. Patients for whom drug intervention is clearly recommended according to the 2022 edition of the European Society of Cardiology Guidelines on Cardio-Oncology.","ALL","18 Years","75 Years",{"count":68,"type":69},524,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","This is a prospective, randomized, controlled, multi-center phase III clinical trial that intends to evaluate the role of early cardiovascular intervention based on impedance cardiography in patients with locally advanced non-small cell lung cancer receiving radical radiochemotherapy±immunotherapy.",[75,76],"Non-small Cell Lung Cancer","Cardiovascular Complication",[75,78,79,80],"Cardiovascular Intervention","Impedance Cardiography","Cardiovascular Event","2025-11-14",{"date":83,"type":84},"2025-11-18","ACTUAL",{"date":86,"type":84},"2021-06-01",{"date":88,"type":69},"2026-07-01",{"name":5,"class":6},1]